Hims & Hers Health, Inc. Class A Common Stock (HIMS)

The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant Novo Nordisk (NYSE: NVO). The deal, which effectively ends a high-stakes patent dispute, has propelled HIMS shares to record highs, closing the

Brokerages have turned bullish on HIMS since its deal with Novo Nordisk earlier this week, with Barclays raising the stock’s price target to $29.

Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents.

Hims & Hers Health has gotten torched over the last six months - since September 2025, its stock price has dropped 55.2% to $23.21 per share. This may have i...

Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk.

As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a "wellness-lite" platform for hair loss and erectile dysfunction, Hims & Hers has evolved into a diversified healthcare titan. Today, the company finds itself [...]

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners.

On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile.

The financial landscape on March 9, 2026, has reached a critical tipping point, marking one of the most aggressive sector rotations in modern market history. As technology-heavy indices struggle to find their footing under the weight of "AI fatigue" and new trade pressures, investors have staged a massive exodus into

Hims & Hers stock traded more than 40% higher after the deal was announced.

Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 41.7% in the morning session after the company announced a collaboration wi...

Date: March 9, 2026Sector: Healthcare TechnologyCompany: Hims & Hers Health, Inc. (NYSE: HIMS) Introduction As of March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at perhaps the most critical juncture in its nine-year history. Once viewed as a disruptive "millennial-focused" telehealth startup specializing in hair loss and sexual health, the company [...]

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

Data from Stocktwits showed that retail sentiment on SPY and QQQ remains ‘bearish.’

Lupton Capital CEO Jonah Lupton said the potential agreement could include both injectable and oral GLP-1 drugs.